Provention Bio

189 articles about Provention Bio

• Provention Bio to Report Third Quarter 2019 Financial Results and Host Conference Call on Tuesday, November 5, 2019

  10/29/2019

  Provention Bio, Inc., a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, announced that it will report its third quarter 2019 financial results on Tuesday, November 5, 2019.

• Provention Bio Announces PRV-031 (Teplizumab) Granted PRIME Designation by the European Medicines Agency

  10/24/2019

  Provention Bio, Inc. announced the European Medicines Agency has granted PRV-031 PRIority MEdicines designation for the prevention or delay of clinical type 1 diabetes in individuals at-risk of developing the disease.

• 

  Provention Bio’s Crohn’s Disease Drug Flunks Mid-Stage Trial

  10/23/2019

  The drug showed what the company is calling a “substantial improvement in this symptom-driven score” at the 12-week point, but it did not differentiate from placebo.

• Provention Bio Reports Top Line Results from Phase 2a PRINCE Clinical Trial with PRV-6527, an Oral CSF-1R Inhibitor, in Patients with Moderate to Severe Crohn's Disease

  10/22/2019

  Excellent Safety Profile and Improvements in Clinically Relevant Secondary Endpoints (Endoscopy and Histology) Support Further Development by a Partner

• 

  BioSpace Movers & Shakers, Sept. 27

  9/27/2019

  Biotech and pharma companies strengthen their leadership teams and boards of directors with this week's appointments.

• Sean Doherty Joins Provention Bio Board of Directors

  9/26/2019

  T1D Fund Executive Chairman and Former Bain Capital Managing Director Brings Extensive Financial Expertise and Deep Knowledge of Therapeutics Landscape

• Provention Bio to Present at the 2019 Cantor Global Healthcare Conference

  9/25/2019

  Provention Bio, Inc. announced that management will present at the 2019 Cantor Global Healthcare Conference on Wednesday, October 2, 2019, at 4:45 pm E.T. The conference is being held at the InterContinental New York Barclay Hotel, New York, NY.

• Provention Bio Reiterates Regulatory Strategy for PRV-031 and Announces Completion of Follow-on Financing

  9/24/2019

  Provention Bio, Inc., (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today reiterated its regulatory strategy regarding PRV-031 (teplizumab) for the prevention or delay of clinical type 1 diabetes (T1D) in individuals at-risk of developing the disease

• Provention Bio Announces Pricing of $40 Million Public Offering of Common Stock - Sept. 18, 2019

  9/19/2019

  Provention Bio, Inc. announced the pricing of its previously announced underwritten registered public offering of 5,000,000 shares of its common stock, offered at a public offering price of $8.00 per share for expected gross proceeds of $40.0 million, before deducting underwriting discounts and other estimated offering expenses.

• Provention Bio Announces Proposed Public Offering of Common Stock - Sept. 18, 2019

  9/18/2019

  Provention Bio, Inc. announced that it has commenced an underwritten public offering of shares of its common stock.

• Provention Bio to Present at the H.C. Wainwright 21st Annual Global Investment Conference

  9/5/2019

  Provention Bio, Inc. announced that management will present at the H.C. Wainwright 21st Annual Global Investment Conference on Tuesday, September 10, 2019, at 8:45 am E.T. The conference is being held at the Lotte New York Palace, New York, NY.

• 

  BioSpace Movers & Shakers, Aug. 23

  8/23/2019

  Biopharma companies strengthen their senior leadership teams and boards of directors with this week's appointments.

• Provention Bio Announces Key Addition to its Leadership Team

  8/20/2019

  Appoints Dr. Sherron Kell as SVP of Clinical Development and Program Lead for PRV-031 (Teplizumab)

• Provention Bio Initiates Phase 1b/2a PREVAIL Clinical Trial Evaluating PRV-3279 in Lupus

  8/8/2019

  Bispecific Diabody Designed to Intercept B-Cell Mediated Autoimmune Diseases

• Provention Bio Reports Second Quarter 2019 Financial Results

  8/6/2019

  PRV-031 Granted Breakthrough Therapy Designation for the Delay or Prevention of Clinical Type 1 Diabetes in At-Risk Individuals

• Provention Bio Announces Breakthrough Therapy Designation for Teplizumab (PRV-031) for the Prevention or Delay of Clinical Type 1 Diabetes in At-Risk Individuals

  8/5/2019

  BTD is an FDA program designed to expedite the development and review of therapeutic candidates intended to treat serious or life-threatening diseases. 

• Tiziana Life Science reports Independent Third Party Article in New England Journal of Medicine on Intravenous Treatment with a Humanized Anti-CD3 mAb showing delays in progression of Type 1 Diabetes

  7/1/2019

  Independent third party Phase 2 results show Teplizumab, a mouse derived humanized anti-CD3 monoclonal antibody (mAb) significantly slowed progression of Type 1 diabetes in high risk population

• 

  Clinical Catch-up for June 10-14

  6/17/2019

  Last week there were quite a few clinical trials whose data were presented. Many were at the American Diabetes Association 79th Scientific Sessions, while others were presented at separate meetings or independently. Here’s a look.

• Provention Bio Announces Termination of Public Offering of Common Stock

  6/13/2019

  Provention Bio, Inc. announced that it has terminated the public offering of common stock previously announced on June 10, 2019.

• Provention Bio Announces Proposed Public Offering of Common Stock

  6/10/2019

  Provention Bio, Inc. announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to a registered underwritten public offering of 5,500,000 shares of its common stock.